Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 1;5(10):1504-1506.
doi: 10.1001/jamaoncol.2019.2963.

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

Feng Wang  1 , Qi Zhao  1 , Ying-Nan Wang  1 , Ying Jin  1 , Ming-Ming He  1 , Ze-Xian Liu  1 , Rui-Hua Xu  1
Affiliations

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

Feng Wang et al. JAMA Oncol. .

Erratum in

  • Error in Figure 2B Number at Risk Table.
    [No authors listed] [No authors listed] JAMA Oncol. 2019 Oct 1;5(10):1513. doi: 10.1001/jamaoncol.2019.4168. JAMA Oncol. 2019. PMID: 31513237 Free PMC article. No abstract available.

Abstract

This cohort study analyzes the medical records of 47 721 patients with various cancer types with POLE/POLD1 mutations to evaluate whether the mutations were associated with immunotherapy outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Prevalence of POLE/POLD1 Mutations in 47 721 Patients With Different Cancer Types
CNS indicates central nervous system.
Figure 2.
Figure 2.. Overall Survival of Patients With POLE/POLD1 Mutations vs Those Without or With MSI-H
MSI-H indicates patients who have high levels of microsatellite instability; Mut indicates patients with POLE/POLD1 mutations; WT indicates patients without mutations.
See this image and copyright information in PMC

Comment in

References

    1. Samstein RM, Lee CH, Shoushtari AN, et al. . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202-206. doi:10.1038/s41588-018-0312-8 - DOI - PMC - PubMed
    1. Rayner E, van Gool IC, Palles C, et al. . A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16(2):71-81. doi:10.1038/nrc.2015.12 - DOI - PubMed
    1. Palles C, Cazier JB, Howarth KM, et al. ; CORGI Consortium; WGS500 Consortium . Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136-144. doi:10.1038/ng.2503 - DOI - PMC - PubMed
    1. Li HD, Cuevas I, Zhang M, et al. . Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. J Clin Invest. 2018;128(9):4179-4191. doi:10.1172/JCI122095 - DOI - PMC - PubMed
    1. Mehnert JM, Panda A, Zhong H, et al. . Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6):2334-2340. doi:10.1172/JCI84940 - DOI - PMC - PubMed